Diabetes on the Net is intended for healthcare professionals

How to assess frailty in your practice and what treatment options should you consider

This video was originally broadcasted on 1 July 2020

This promotional webinar series and respective materials have been developed, organised and funded by Novo Nordisk.
For healthcare professionals only. 

Promotional information on insulin degludec (Tresiba®) will be discussed in this webinar. Click here to view prescribing information and adverse event reporting information for insulin degludec (Tresiba®). Insulin degludec (Tresiba®) is indicated for the treatment of diabetes mellitus in adults, adolescents and children from the age of 1 year.